Literature DB >> 18475200

Additive effects of combined application of multiple hERG blockers.

Michael Margulis1, Steve Sorota.   

Abstract

Pro-arrhythmia by noncardiac drugs has become an important safety concern in the pharmaceutical industry. The most common underlying mechanism for induction of arrhythmias by noncardiac drugs is off-target block of the native cardiac repolarizing current, I Kr. The pore-forming subunit of I Kr is encoded by the human ether-a-go-go related gene (hERG), and in vitro measurements of hERG activity has become a standard component of drug safety evaluations. hERG/I Kr channels are blocked by a wide array of different chemical series; therefore, patients could be exposed to multiple blockers. There are few published studies addressing whether multiple blockers will exert independent actions on hERG channels. Whole cell patch clamp was used to evaluate the potential for cooperative effects when 2 hERG blocking agents were applied simultaneously. Cisapride, quinidine, fluvoxamine, and BeKm-1 were selected as representative agents binding to: (1) hydrophobic residues in the inner vestibule (cisapride and quinidine, the most frequent sites of interaction), (2) an extracellular segment near the pore (BeKm-1) or, (3) an unknown site (fluvoxamine). No synergistic blocking actions were seen. In some cases block was slightly less than additive. On balance, the results are consistent with additive and independent actions with simultaneous application of 2 hERG blockers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18475200     DOI: 10.1097/FJC.0b013e31817532ee

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data.

Authors:  Andreas D Meid; Anna von Medem; Dirk Heider; Jürgen-Bernhard Adler; Christian Günster; Hanna M Seidling; Renate Quinzler; Hans-Helmut König; Walter E Haefeli
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

2.  Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death.

Authors:  Timothy F Simpson; James W Salazar; Eric Vittinghoff; Joanne Probert; Alan Iwahashi; Jeffrey E Olgin; Phillip Ursell; Amy Hart; Ellen Moffatt; Zian H Tseng
Journal:  JAMA Intern Med       Date:  2020-05-01       Impact factor: 21.873

Review 3.  Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening.

Authors:  Alec S T Smith; Jesse Macadangdang; Winnie Leung; Michael A Laflamme; Deok-Ho Kim
Journal:  Biotechnol Adv       Date:  2016-12-20       Impact factor: 14.227

4.  Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature.

Authors:  Andreas D Meid; Irene Bighelli; Sarah Mächler; Gerd Mikus; Giuseppe Carrà; Mariasole Castellazzi; Claudio Lucii; Giovanni Martinotti; Michela Nosè; Giovanni Ostuzzi; Corrado Barbui; Walter E Haefeli
Journal:  Ther Adv Psychopharmacol       Date:  2017-08-28

5.  The macrolide drug erythromycin does not protect the hERG channel from inhibition by thioridazine and terfenadine.

Authors:  Aziza El Harchi; Andrew S Butler; Yihong Zhang; Christopher E Dempsey; Jules C Hancox
Journal:  Physiol Rep       Date:  2020-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.